Cargando…

Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products

This cross-sectional study evaluates the association of generic competition and changes in product coverage and cost-sharing by using Medicare data and estimated out-of-pocket costs for the oral specialty drug abiraterone.

Detalles Bibliográficos
Autores principales:	Gupta, Arjun, Antonarakis, Emmanuel S., Blaes, Anne H., Booth, Christopher M., Dusetzina, Stacie B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526080/ https://www.ncbi.nlm.nih.gov/pubmed/36178694 http://dx.doi.org/10.1001/jamanetworkopen.2022.31475

Ejemplares similares

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
por: Erath, Alexandra, et al.
Publicado: (2020)

Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US
por: Shafer, Paul R., et al.
Publicado: (2022)

Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
por: Yeung, Kai, et al.
Publicado: (2021)

Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit
por: Rotenstein, Lisa S., et al.
Publicado: (2018)

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
por: Salam, Tabassum, et al.
Publicado: (2023)

Progressivity of out-of-pocket costs for Medicare-subsidised services and medicines in Australia.
por: Di Law, Hsei, et al.
Publicado: (2022)

The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up
por: Etteldorf, Andrew, et al.
Publicado: (2022)

Price Comparison of Human and Veterinary Formulations of Common Medications
por: Haque, Waqas, et al.
Publicado: (2022)

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
por: Tseng, Chien-Wen, et al.
Publicado: (2020)

Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020
por: Kyle, Michael Anne, et al.
Publicado: (2022)

Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

Out-of-pocket health spending among Medicare beneficiaries: Which chronic diseases are most costly?
por: Fong, Joelle H.
Publicado: (2019)

Potential Cost Savings With Low-Dose Abiraterone in the United States
por: Premnath, Naveen, et al.
Publicado: (2020)

Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps
por: Dusetzina, Stacie B., et al.
Publicado: (2021)

16. Attributable Mortality, Healthcare Costs and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2021)

Accuracy of Physician Estimates of Out-of-Pocket Costs for Medication Filling
por: Sloan, Caroline E., et al.
Publicado: (2021)

Estimates of Insulin Out-of-Pocket Cap–Associated Prescription Satisfaction, Adherence, and Affordability Among Medicare Beneficiaries
por: Li, Minghui, et al.
Publicado: (2023)

Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
por: Bartlett, Victoria L., et al.
Publicado: (2020)

Is expanding Medicare coverage cost-effective?
por: Franks, Peter, et al.
Publicado: (2005)

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
por: Trish, Erin, et al.
Publicado: (2021)

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
por: Luo, Jing, et al.
Publicado: (2020)

ENTERING MEDICARE ADVANTAGE FROM EMPLOYER-SPONSORED PLANS: CHANGE IN OUT-OF-POCKET COSTS AND UTILIZATION AT AGE 65
por: Hames, Alexandra Glynn, et al.
Publicado: (2022)

Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2022)

Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs
por: Liu, Judith, et al.
Publicado: (2022)

Evolution of Medicaid Coverage of Medicare Cost Sharing
por: Carpenter, Letty
Publicado: (1998)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Estimating Client Out-of-Pocket Costs for Accessing Voluntary Medical Male Circumcision in South Africa
por: Tchuenche, Michel, et al.
Publicado: (2016)

Impact of Out-of-Pocket Cost on Herpes Zoster Vaccine Uptake: An Observational Study in a Medicare Managed Care Population
por: Tao, Zhuliang, et al.
Publicado: (2018)

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance
por: Fendrick, A. Mark, et al.
Publicado: (2021)

Changes in Out-of-Pocket Spending and Catastrophic Health Care Expenditures Associated With Medicare Eligibility
por: Scott, John W., et al.
Publicado: (2021)

Correction: Estimating Client Out-of-Pocket Costs for Accessing Voluntary Medical Male Circumcision in South Africa
por: Tchuenche, Michel, et al.
Publicado: (2017)

Out of Pocket Costs and Variation in Panniculectomy Procedures
por: Oleru, Olachi, et al.
Publicado: (2023)

Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
por: Lakdawalla, Darius, et al.
Publicado: (2021)

Cost Variability of Suggested Generic Treatment Alternatives Under the Medicare Part D Benefit
por: Patel, Rajul A., et al.
Publicado: (2014)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
por: Fang, Mike, et al.
Publicado: (2017)

Trends in Out-of-Pocket Cost of Glucagon, 2010-2020
por: Zupa, Margaret, et al.
Publicado: (2022)

Association of Out-of-Pocket Pharmacy Costs with Adherence to Varenicline
por: Suehs, Brandon T., et al.
Publicado: (2014)

Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence
por: Galaznik, Aaron, et al.
Publicado: (2014)

Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kciisgt3n6j5giu8es280b7fn4